CAR Peptide
CAR peptide is a cell-penetrating STAT3-inhibiting peptide with research applications in cancer, neuroinflammation, and autoimmune conditions, blocking STAT3 dimerization and transcriptional activity.
CAR peptide is a synthetic cell-penetrating peptide designed to inhibit Signal Transducer and Activator of Transcription 3 (STAT3) by preventing its dimerization and subsequent nuclear translocation. STAT3 is constitutively activated in a wide range of cancers and chronic inflammatory conditions, making it a high-value therapeutic target.
Overview
STAT3 functions as a convergence point for multiple oncogenic and inflammatory signaling pathways. When activated by JAK kinases, STAT3 monomers are phosphorylated at tyrosine 705 (Y705), dimerize through reciprocal SH2 domain-phosphotyrosine interactions, and translocate to the nucleus where they drive transcription of target genes including Bcl-2, Bcl-xL, Mcl-1, cyclin D1, VEGF, MMP-2, and IL-10. In normal cells, STAT3 activation is transient and tightly regulated by SOCS proteins and phosphatases. However, in many cancers and chronic inflammatory conditions, STAT3 becomes constitutively active, creating a self-reinforcing loop of survival signaling, immune evasion, and proliferation. CAR peptide disrupts this loop by competitively binding the SH2 domain and preventing dimerization, effectively silencing STAT3-dependent gene transcription without affecting upstream kinase activity.
Mechanism of Action
CAR peptide inhibits STAT3 through direct competition at the SH2 domain dimerization interface. Under normal signaling, JAK kinases phosphorylate STAT3 at Y705 in response to cytokine receptor activation (IL-6, IL-10, EGF, HGF, and others). Phosphorylated STAT3 monomers then dimerize through reciprocal SH2-pY705 interactions, forming parallel dimers that expose a nuclear localization signal and bind importin-alpha for nuclear transport.
CAR peptide contains a sequence that mimics the phosphotyrosine-containing region of STAT3, binding to the SH2 domain pocket with sufficient affinity to prevent endogenous STAT3-STAT3 dimerization. This results in accumulation of phosphorylated but monomeric STAT3 in the cytoplasm, which is rapidly dephosphorylated by constitutive phosphatases (TC-PTP, SHP-1/2) and returned to the inactive pool.
The cell-penetrating component of CAR peptide enables direct cytoplasmic delivery without the need for receptor-mediated endocytosis, overcoming a major limitation of traditional peptide therapeutics. Once internalized, the STAT3-binding domain is released and available for target engagement.
Downstream consequences of STAT3 inhibition include:
- Reduced anti-apoptotic gene expression (Bcl-2, Bcl-xL, Mcl-1, survivin)
- Decreased proliferative signaling (cyclin D1, c-Myc)
- Suppressed angiogenesis (VEGF, HIF-1alpha)
- Restored anti-tumor immunity (reduced IL-10, TGF-beta; increased MHC-I expression)
- Diminished metastatic potential (reduced MMP-2, MMP-9)
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Cancer: Constitutive STAT3 Activation
STAT3 is constitutively activated in approximately 70% of human cancers, including breast, lung, colorectal, ovarian, prostate, pancreatic, head and neck squamous cell carcinoma, melanoma, and hematological malignancies. In these cancers, persistent STAT3 signaling drives multiple hallmarks of malignancy simultaneously. STAT3-inhibiting peptides have demonstrated anti-proliferative and pro-apoptotic effects in cancer cell lines with constitutive STAT3 activation, inducing cell death selectively in STAT3-dependent tumors while sparing normal cells where STAT3 activity is transient and dispensable.
Neuroinflammation
STAT3 activation in microglia and astrocytes drives neuroinflammatory cascades implicated in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injury. Activated STAT3 promotes production of IL-6, TNF-alpha, and nitric oxide by reactive glia, creating a neurotoxic microenvironment. STAT3 inhibition by peptide approaches reduces glial activation and inflammatory cytokine production in preclinical models, offering potential neuroprotective benefits distinct from direct neuronal protection strategies like humanin or colivelin.
Autoimmune Conditions
STAT3 gain-of-function mutations cause early-onset multi-organ autoimmunity in humans, confirming STAT3's role in immune dysregulation. In more common autoimmune conditions (rheumatoid arthritis, inflammatory bowel disease, psoriasis), STAT3 hyperactivation in T cells drives pathological Th17 differentiation and IL-17 production. STAT3-inhibiting peptides suppress Th17 polarization and reduce IL-17-dependent inflammation in preclinical autoimmune models.
Immune Checkpoint Modulation
STAT3 drives expression of PD-L1 in tumor cells and promotes immunosuppressive myeloid-derived suppressor cell (MDSC) differentiation in the tumor microenvironment. By inhibiting STAT3, CAR peptide-class agents can potentially restore anti-tumor immunity by reducing PD-L1-mediated T cell exhaustion and suppressing MDSC accumulation. This mechanism is complementary to checkpoint inhibitor immunotherapy (anti-PD-1/PD-L1 antibodies).
Safety Profile
STAT3 inhibition carries theoretical risks because STAT3 has physiological roles in wound healing, liver regeneration, cardiac protection during ischemia, and immune defense against infections. Complete STAT3 blockade could impair these protective functions. However, peptide-based STAT3 inhibitors like CAR peptide offer advantages over small molecule inhibitors: (1) competitive rather than irreversible inhibition allows dynamic regulation, (2) short half-life limits duration of suppression, and (3) cell-penetrating peptide targeting can potentially be engineered for tissue selectivity. Preclinical studies have not reported significant systemic toxicity at effective doses, though formal safety pharmacology and toxicology data are limited. Immunosuppression, impaired wound healing, and hepatotoxicity are monitored endpoints in STAT3 inhibitor development programs.
Pharmacokinetic Profile
- Half-life
- Not established in humans
Quick Start
- Route
- Subcutaneous injection, intraperitoneal (research)
Research Protocols
intraperitoneal Injection
Peak intracellular concentrations are achieved within 1-2 hours of intraperitoneal administration in rodent models.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Lipopolysaccharide | 1-10 mg | Per protocol | — |
subcutaneous Injection
Administered via subcutaneous injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| 5-20 mg/kg IP daily or every other day | 5-20 mg | Every other day | 2-4 weeks |
| 1-10 mg/kg IP | 1-10 mg | Per protocol | — |
oral
Peptide inhibitors offer higher target selectivity (fewer off-target effects) but shorter half-life and limited oral bioavailability. Small molecules offer oral dosing and longer duration of action but greater potential for off-target toxicity.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Lipopolysaccharide | 1-10 mg | Per protocol | — |
Interactions
Peptide Interactions
STAT3 inhibition reduces tumor PD-L1 expression and suppresses immunosuppressive MDSC differentiation. Combining STAT3 peptide inhibitors with anti-PD-1 antibodies could enhance anti-tumor immune responses by simultaneously removing the PD-1/PD-L1 brake and restoring immune cell function in the t...
For autoimmune and inflammatory indications, combining STAT3 inhibition (which blocks Th17 differentiation) with KPV's alpha-MSH-derived anti-inflammatory activity could provide multi-layered suppression of pathological inflammation while preserving protective immune function through orthogonal m...
What to Expect
What to Expect
Peak intracellular concentrations are achieved within 1-2 hours of intraperitoneal administration in rodent models.
In xenograft tumor models, STAT3-inhibiting peptides have been administered at 5-20 mg/kg IP daily or every other day for 2-4 weeks.
Continued use as directed
Quality Indicators
What to look for
- Oral administration available
Caution
- Short half-life may require frequent dosing
Red flags
- Liver toxicity concerns reported
Frequently Asked Questions
References (10)
- [8]Johnson et al -- STAT3 as a therapeutic target in cancer: current and future perspectives Cancer Res (2023)
- [9]Zou et al -- Cell-penetrating peptides as STAT3 inhibitors: design, synthesis, and anti-tumor activity Eur J Med Chem (2022)
- [10]Li et al -- STAT3 inhibition in neuroinflammation: implications for neurodegenerative disease therapy J Neuroinflammation (2023)
- [1]Turkson et al *Mol Cell Biol* Mol Cell Biol (2001)
- [2]Yue & Bhagat *J Biol Chem* J Biol Chem (2008)
- [3]Yu et al *Nat Rev Cancer* Nat Rev Cancer (2009)
- [4]
- [5]Debnath et al *ACS Chem Biol* ACS Chem Biol (2012)
- [6]Bournazou & Bhagat *JAK-STAT* JAK-STAT (2015)
- [7]Johnson et al *Nat Rev Drug Discov* Nat Rev Drug Discov (2018)
Calcitonin Gene-Related Peptide (CGRP)
Calcitonin Gene-Related Peptide (CGRP) is a 37-amino-acid neuropeptide and the most potent endogenous vasodilator known. Existing as α-CGRP (neural) and β-CGRP (enteric) isoforms, it signals through the CLR/RAMP1 receptor complex and plays a central role in migraine pathophysiology, neurogenic inflammation, and cardiovascular protection.
Cardiogen
Cardiogen (AEDR) is a synthetic tetrapeptide bioregulator that modulates fibroblast activity in cardiac tissue, studied for its cardioprotective effects and potential anti-tumor properties. Research suggests it may improve outcomes in heart failure, hypertension, and sarcoma through regulation of apoptosis and tissue remodeling pathways.